Copyright infringement not intended
Picture Courtesy: timesofindia.indiatimes.com
Context: Indian Immunologicals Ltd (IIL), a subsidiary of the National Dairy Development Board (NDDB) and a leading biopharmaceutical company in Hyderabad, launched India's first indigenously developed Hepatitis A vaccine named 'Havisure.'
India's First Hepatitis A Vaccine 'Havisure' Launch
- 'Havisure' is crucial in preventing Hepatitis A, a highly contagious liver infection transmitted through the faecal-oral route via contaminated food or water, addressing a significant public health challenge.
- The development of 'Havisure' reflects the Atma Nirbhar Bharat initiative, as it reduces dependency on imported Hepatitis A vaccines. IIL's efforts in developing the vaccine signify a commitment to self-reliance.
- The vaccine is recommended for routine immunization in children, administered in two doses. The first dose is given above 12 months of age, with the second dose at least 6 months after the first.
- In addition to routine immunization for children, the vaccine is recommended for individuals at risk of exposure, those travelling to regions with high hepatitis A prevalence, and individuals with occupational risk or suffering from chronic liver diseases.
Must Read Articles:
Q. What is the significance of “Havisure”, frequently seen in the news:
A) It requires a unique three-dose schedule for complete protection.
B) It offers significantly longer-lasting immunity compared to existing vaccines.
C) It represents a major step towards self-reliance in vaccine production for India.
D) It is significantly cheaper than other available Hepatitis A vaccines.
Explanation: Havisure's development marks a significant milestone in India's efforts to become self-sufficient in vaccine production, reducing reliance on imports and potentially making the vaccine more accessible to the population.